Related Experiment Video
Updated: Jun 20, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Glioblastoma Multiforme Oncogenomics and Signaling Pathways
Okezie O Kanu1, Betsy Hughes, Chunhui Di
1Lagos University Teaching Hospital, Lagos, Nigeria.
Clinical Medicine. Oncology
|September 25, 2009
Summary
Glioblastoma multiforme (GBM) is a common, aggressive brain tumor. Advances in understanding GBM genetics and stem cell biology offer new therapeutic targets for this challenging disease.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults.
- It accounts for over 50% of primary central nervous system gliomas.
- GBM can arise de novo (primary GBM) or progress from lower-grade astrocytomas (secondary GBM), potentially representing distinct entities.
Purpose of the Study:
- To review the current understanding of glioblastoma multiforme oncogenomics.
- To explore critical signaling pathways involved in GBM development.
- To discuss the role of glioma stem cell biology and potential new therapeutic targets.
Main Methods:
- Review of current scientific literature on glioblastoma multiforme.
- Analysis of genetic alterations and signaling pathways.
- Examination of glioma stem cell biology and neoangiogenesis.
Main Results:
- Significant progress has been made in elucidating GBM's genetic landscape and signaling pathways.
- Glioma stem cell biology and neoangiogenesis are emerging as critical areas of research.
- Novel targeted therapies are being developed based on this increased genetic knowledge.
Conclusions:
- Despite decades of treatment, survival rates for glioblastoma multiforme remain poor.
- A deeper understanding of GBM's genetic underpinnings and cellular mechanisms is crucial.
- Emerging research in oncogenomics, signaling pathways, and stem cell biology holds promise for future therapeutic strategies.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...